A Phase I/II Study of Nivolumab in Combination with 5-azacytidine in pediatric patients with relapsed/refractory acute myeloid leukemia (BMS reference CA209-9JY)
Study of Nivolumab in Combination with 5-Azacytidine in Acute Myeloid Leukemia (AML) - Children and Adults Age 1 to 30
Sponsor: TACL
Enrolling: Male and Female Patients
IRB Number: AAAS4180
U.S. Govt. ID: NCT03825367
Contact: Nobuko Hijiya: 212-305-9770 / nh2636@cumc.columbia.edu
Additional Study Information: The purpose of this study is to find out if the drugs called Nivolumab and 5-Azacytidine can be given safely in children and young adults with Acute Myeloid Leukemia (AML) which has come back after treatment or has not responded to standard therapy. These drugs are thought to work by turning on genes that limit the growth of cancer cells. The study drugs will be given for 2 courses of chemotherapy duration based on how well the participants will tolerate the study drug and response, each course is 29-36 days long. Treatment for the 2 courses of therapy will last about 2-3 months.
Nobuko Hijiya, MD
Do You Qualify?
Are you (or your child) between the ages of 1 and 30 years of age? Yes No
Have you (or your child) been diagnosed with acute myeloid leukemia (AML)? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Nobuko Hijiya